Jupiter Neurosciences Common Stock Today
| JUNS Stock | USD 0.33 -0.01 -2.94% |
Performance 0High 0 · Weak | Odds Of Distress HighLow 88 · Critical |
Jupiter Neurosciences currently maintains a market price of $0.33, with performance measured at a 2.94% decrease on the day with an intraday range between $0.33 and $0.35. Jupiter Neurosciences currently reflects 88% projected probability of financial distress, aligning with a substantially elevated probability. Jupiter Neurosciences has delivered negative risk-adjusted returns over the past 90 trading days. The performance scores are measured across the period from February 9, 2026 to May 10, 2026. Learn more.
IPO Date 3rd of December 2024 | Asset Type Stock | Category Healthcare | Classification Health Care |
Follow Valuation Profit Patterns Odds of Bankruptcy
Jupiter Neurosciences Common (JUNS) is listed on NASDAQ Exchange in USA. Jupiter Neurosciences operates within the Pharmaceuticals segment. For market cap analysis, Jupiter Neurosciences Common is currently valued at $12.07 million and falls into the micro-cap segment of pharmaceuticals. Associated fundamentals relevant to market cap include about 36.28 million shares outstanding and enterprise value near $13.94 million. Jupiter Neurosciences has 75,528 shares sold short (0.61 days to cover). Jupiter Neurosciences is a research-driven pharmaceutical developer where revenue is driven by pipeline advancement, approvals, and patent-protected revenue. JUNS has return on total asset (ROA) of -94.64% indicating the asset base is not generating profit. Negative, indicating a net loss relative to revenue. Jupiter Neurosciences also reports a return on stockholder's equity (ROE) of -738.83%, which implies that it generated no returns to current stockholders. Jupiter Neurosciences financial stability analysis Ownership Allocation Jupiter Neurosciences has a large amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Jupiter Ownership Details Check how we calculate scores
Stock Notable Updates
| Legal Name | Jupiter Neurosciences, Inc. Common Stock |
| Co-Founder, CEO & Chairman of the Board | Christer Rosen |
| Chairman | Claes MD |
| President Chief Business Officer & Director | Alison MA |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare, (View all Sectors) |
Latest disclosures for Jupiter Neurosciences Common show a Gross Profit Margin of 65.0%, an Operating Margin of -12886.7%, and a Return On Capital Employed of 511.0%. Capital allocation and earnings structure point to Jupiter Neurosciences having pressured financial positioning. Profitability is currently challenged, with return on assets below breakeven.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0 | 0 |
|
| |||||
| Gross Profit Margin | 65.00% | 73.00% |
|
| |||||
| Total Current Liabilities | $5.88 million | $7.4 million |
|
| |||||
| Total Assets | $5.84 million | $5.56 million |
|
| |||||
| Total Current Assets | $5.07 million | $4.82 million |
|
|
Current Assets
Latest disclosures for Jupiter Neurosciences Common show $5.8 million in Total Assets, a Return On Tangible Assets of -163.0%, and a Debt To Assets of 91.0%. Jupiter Neurosciences Common's key financial metrics profile is further characterized by $439 thousand in Non Current Assets Total.
Jupiter Neurosciences Historical Income Statement
Selling General Administrative stood at $6.84 million as of December 31, 2025. Meanwhile, Operating Income is broadly unchanged at $-8.91 million, although Interest Expense is broadly unchanged around $66,020. View More FundamentalsJupiter Neurosciences Common Against Markets
| NYA | 0.30 | ||||
| JUNS | 2.94 |
| Competition | Compare Correlations |
Stock Overview, Methodology & Data Sources
Jupiter Neurosciences is listed within United States regulated exchanges. Headquarters are in 1001 North US Highway 1, Jupiter, FL, United States, 33477. Recent market snapshot indicates market cap 12.07 million, P/B 227.66. Jupiter Neurosciences operates in Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Operating metrics are tied to how the market is pricing risk. The company is currently operating at a loss.
Methodology
Unless otherwise specified, financial data for Jupiter Neurosciences Common is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Jupiter (USA Stocks:JUNS) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: We use public filings and market reference sources with disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR as reference inputs. Data may be normalized and can be delayed. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Jupiter Neurosciences Common may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Raphi Shpitalnik, Junior Member of Macroaxis Editorial Board
Jupiter Neurosciences Corporate Executives
Board and executive analysis for Jupiter Neurosciences Common is useful because governance quality can influence capital allocation, accountability, and long-term strategic consistency. This becomes more valuable when seeking to compare oversight quality across firms that may otherwise look financially similar.
| Marshall Hayward | Co-Founder, Chief Scientific Officer & Director | Profile | |
| Alexander Rosen | Co-Founder & Chief Administrative Officer | Profile | |
| Saleem Elmasri | CFO & Secretary | Profile |
Additional Tools for Jupiter Stock Analysis
Stock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.Stocks DirectoryFind actively traded stocks across global marketsIdea OptimizerApply mean-variance optimization to pre-computed thematic ideas and evaluate candidate allocationsGlobal CorrelationsFind global opportunities by holding instruments from different marketsMy Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you likeStock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websitesETFsFind actively traded Exchange Traded Funds (ETF) from around the worldSign In To MacroaxisSign in to explore Macroaxis' wealth optimization platform and fintech modulesEquity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities